MyDrHank review

MyDrHank offers sermorelin and NAD⁺ in more than one route, with medication, clinical review and delivery advertised as included. Its product pages show starting monthly figures rather than a complete payment schedule. Confirm the selected plan, first charge, renewal and cancellation terms before paying; the public prices do not establish a twelve-month commitment or a month-to-month debit.

Dr. Hank, LLC operates an online telehealth platform with longevity, weight-management, sexual-health and hair-care categories. The longevity pages reviewed here describe sermorelin injection and NAD⁺ injection or nasal spray. Independent licensed clinicians decide whether prescribing is appropriate, and licensed pharmacy partners dispense. The product menu is not evidence that any treatment is suitable for an individual patient.

An online assessment is reviewed by a licensed clinician, who decides whether prescribing is appropriate. The pages advertise a free consultation, delivery and ongoing support. Dr. Hank, LLC operates the platform; its terms say the company does not establish the treating clinician relationship itself. Pharmacy partners are described as licensed U.S. pharmacies, with a current list available on request. The public pages do not identify a selected prescription’s dispenser, publish a complete state list or set out product-specific cancellation and refund deadlines.

Sermorelin injection and NAD⁺ nasal spray are advertised from $137/month; NAD⁺ injection from $155/month. These are starting figures. The readable product pages do not tie them to a particular plan length or disclose a full first charge, renewal amount or shorter-plan price. Medication, clinician review, support and delivery are advertised as included. Ask for the payment schedule and supply quantity in writing, including any commitment, before choosing a plan. No current public cancellation or refund schedule was found in the linked Terms of Use.

Compounded; not FDA-approved. To MyDrHank's credit, the disclaimer is present and correctly worded in the footer of every page and again under each product, and the weight-loss calculator says plainly that its trial figures come from the FDA-approved drugs, not the compounded versions it dispenses. The glutathione pages are a model of how to cite: they name a study of GlyNAC (glycine plus N-acetylcysteine) and then say outright that it did not test glutathione itself and that results may differ. The NAD⁺ pages are the opposite. Both the nasal spray and the injection chart a "6x increase in whole blood NAD+ after 12 weeks" and cite Igarashi and colleagues, npj Aging 2022, which tested oral nicotinamide mononucleotide (NMN) in healthy older men. That is a different molecule, taken by mouth, and it measured a blood level, not a health outcome. The injection page goes further and describes the result as "NAD+ supplementation" with gains in gait speed. The same pages' own footnote says clinical evidence for nasal and injectable NAD⁺ is limited, which is the accurate statement. Injected and intranasal NAD⁺ have no controlled human outcome trials. Sermorelin is presented well: as a growth-hormone-releasing hormone analog that prompts your own pituitary rather than replacing hormone, with endocrinology citations attached. The page's "about 50% rise in IGF-1" is a hormone marker; long-term outcome data for sermorelin are thin. On the hair page, an "FDA-approved active ingredients" banner sits over oral minoxidil (approved as a blood-pressure drug, not for hair loss; only topical minoxidil is approved for that) and over a custom protocol of five compounded formulations, which are not FDA-approved by definition. Individual results vary.